Abstract
The Czech Republic continues to maintain global leadership in the incidence of kidney cancer. The COMPARZ study comparing the first-line efficacy and safety of pazopanib with sunitinib confirmed a comparable therapeutic effect with a better safety profile for pazopanib.
These tolerability data were confirmed by the PISCES study, which compared the subjective perception of tolerability of the two BP inhibitors. Axitinib is a new TK inhibitor registered for second-line treatment of metastatic renal cell carcinoma based on a randomized trial comparing its effect with sorafenib.
In this study, axitinib demonstrated a longer time to disease progression, but this was not transformed into a longer overall survival time. It is also the first study to clearly demonstrate the efficacy of BP inhibitors pretreated with another BP inhibitor.